

Amendments to the Claims:

1. (Currently amended) A method for treating an immune system disorder in a subject in need of such treatment, wherein the disorder is selected from the group consisting of HIV infection, AIDS, and adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID), comprising administering to said subject a compound selected from the group consisting of:

- (a) selective A<sub>1</sub> adenosine receptor antagonists;
  - (b) selective P<sub>2x</sub> purinoceptor antagonists; and
  - (c) a combination of at least one A<sub>1</sub> adenosine receptor antagonist and at least one P<sub>2x</sub> purinoceptor antagonist;
- wherein said compound is administered in an amount effective to treat the immune system disorder.

2. (Canceled)

3. (Original) A method according to Claim 1, wherein the A<sub>1</sub> adenosine receptor antagonist is an antibody that binds the A<sub>1</sub> adenosine receptor.

4. (Original) A method according to Claim 1, wherein the P<sub>2x</sub> purinoceptor antagonist is an antibody that binds the P<sub>2x</sub> purinoceptor.

5. (Currently amended) A method for preventing or delaying the onset of an immune system disorder in a subject in need of such treatment, wherein the disorder is selected from the group consisting of HIV infection, AIDS, and ADA SCID, comprising administering to said subject a compound selected from the group consisting of:

- (a) selective A<sub>1</sub> adenosine receptor antagonists;
- (b) selective P<sub>2x</sub> purinoceptor antagonists; and

(c) a combination of at least one A<sub>1</sub> adenosine receptor antagonist and at least one P<sub>2x</sub> purinoceptor antagonist;  
wherein said compound is administered in an amount effective to prevent or delay the onset of the immune system disorder that would occur in the absence of the administration.

6. (Canceled)

7. (Original) The method according to Claim 5, wherein the A<sub>1</sub> adenosine receptor antagonist is an antibody that binds to the A<sub>1</sub> adenosine receptor.

8. (Original) A method according to Claim 5, wherein the P<sub>2x</sub> purinoceptor antagonist is an antibody that binds to the P<sub>2x</sub> purinoceptor.

9. (Canceled)

10. (Currently amended) The method of Claim 9 1, wherein the treatment is carried out in conjunction with another treatment for HIV infection, ~~or~~ AIDS, or ADA SCID.

11-22. (Canceled)

23. (New) The method according to claim 1, wherein the immune system disorder is HIV infection.

24. (New) The method according to claim 1, wherein the immune system disorder is AIDS.

25. (New) The method according to claim 1, wherein the immune system disorder is ADA SCID.

Appl. No.: 10/713,860  
Amdt. dated July 10, 2007  
Reply to Office Action of January 11, 2007

26. (New) The method according to claim 5, wherein the immune system disorder is HIV infection.

27. (New) The method according to claim 5, wherein the immune system disorder is AIDS.

28. (New) The method according to claim 5, wherein the immune system disorder is ADA SCID.